Clindamycin Phosphate Injection, Solution
Product Images NDC 0338-4114

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clindamycin Phosphate (NDC 0338-4114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clindamycin In 5% Dextrose Structural Formula (Image 01)

Chemical structure diagram of clindamycin phosphate, showing the molecular arrangement including a phosphate group, a sugar moiety, and a nitrogen-containing ring as part of the molecule.*

FDA Label Image

Representative Container Label 0338-3616-50 Panel 1 Of 2 (Image 02)

Label for Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) intravenous injection solution. The label indicates a 50 mL single dose container, sterile and nonpyrogenic, manufactured by Baxter Healthcare Company. It includes dosage strength, usage instructions, storage conditions, and trademark information for PremierProRx.*

FDA Label Image

Representative Container Label 0338-3616-50 Panel 2 Of 2 (Image 03)

The image shows a pink section of packaging labeled with the text 'BAR CODE POSITION ONLY' and a vertical number sequence '30383661500', indicating the designated area for barcode placement on Clindamycin phosphate injection solution packaging from Baxter Healthcare Company.*

FDA Label Image

Representative Carton Label 0338-3616-24 Panel 1 Of 2 (Image 04)

Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) intravenous solution. The label states packaging in 12 single-dose 50 mL containers. Manufactured by Baxter Healthcare Corporation, Deerfield, IL, USA. Storage instructions specify 20° to 25°C (68° to 77°F), with avoidance of temperatures above 30°C.*

FDA Label Image

Representative Carton Label 0338-3616-24 Panel 1 Of 2 (Image 05)

This image shows two identical drug labels for Clindamycin phosphate injection solution, USP 600 mg/50 mL. The labels specify that the drug is for intravenous use, not for rapid injection or intravenous push. Each 50 mL contains clindamycin phosphate equivalent to 600 mg clindamycin, with other ingredients listed. The labels also include dosing and cautionary instructions, storage notes such as sterile and nonpyrogenic status, and the NDC code 0338-3616-24.*

FDA Label Image

Serialization Lbl For 0338-3616-24 (Image 06)

Labels for Clindamycin Injection USP in 5% Dextrose 600 mg/50 mL intravenous solution. The label includes storage instructions to keep at 20°C to 25°C (68°F to 77°F) and avoid temperatures above 30°C. It displays the lot number, expiration date placeholder, serial number, and the manufacturer Baxter Healthcare Corporation under the PREMIER ProRx brand.*

FDA Label Image

Representative Container Label 0338-4114-50 Panel 1 Of 2 (Image 07)

Label for Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (18 mg/mL) intravenous injection solution. It is a 50 mL single dose container, sterile and nonpyrogenic, made by Baxter Healthcare Company. The label includes usage instructions, dosage form, and storage conditions.*

FDA Label Image

Representative Container 0338-4114-50 Panel 2 Of 2 (Image 08)

Label panel for Clindamycin phosphate injection, solution showing a placeholder for a barcode with the text 'BAR CODE POSITION ONLY' and a numeric code beneath it. No product strength or additional details are visible on this image.*

FDA Label Image

Representative Carton Lbl 0338-4114-24 Panel 1 Of 2 (Image 09)

Clindamycin Injection USP in 5% Dextrose 900 mg per 50 mL (18 mg/mL) intravenous solution. The label states it contains 12 single-dose 50 mL containers. Manufactured by Baxter Healthcare Corporation, Deerfield, IL, USA. Storage instructions include maintaining temperature between 20° to 25°C (68° to 77°F) and avoiding temperatures above 30°C.*

FDA Label Image

Representative Carton Lbl 0338-4114-24 Panel 2 Of 2 (Image 10)

Drug information panel for Clindamycin phosphate injection, intravenous, showing two identical sections. Each 50 mL contains 900 mg clindamycin phosphate with excipients listed. Instructions specify it is not for rapid injection or intravenous push. Contains cautionary notes about medication use, series connections, and solution checks.*

FDA Label Image

Representative Serialization Lbl 0338-4114-24 (Image 11)

Label for Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL intravenous injection solution. Includes storage instructions at 20°C to 25°C and warnings to avoid temperatures above 30°C. Manufactured by Baxter Healthcare Company, Deerfield, IL. Lot, expiration date, and serial number placeholders are visible, along with NDC code 0338-4114-24.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.